Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but ... who are jointly developing enfortumab vedotin, an antibody-drug ...

An international clinical trial of a treatment for advanced urothelial cancer has found a new ... is a combination of two drugs—enfortumab vedotin (EV) and pembrolizumab—delivered by infusion ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical ... control rate in patients with advanced urothelial carcinoma (aUC) outside ...

Medscape Medical News, March 11, 2020 GUCS 2020 Unprecedented Response Rate in Advanced Bladder Cancer The combination of enfortumab vedotin plus pembrolizumab as a first-line treatment for ...

A new combination of cancer ... enfortumab vedotin and the immunotherapy pembrolizumab, administered through IV infusions, cut the risk of disease progression or death by 55% in patients with ...

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.

Opens in a new tab or window In the U.S., the economic burden associated with the latest first-line treatments for locally advanced or ... well as the use of enfortumab vedotin plus pembrolizumab ...

Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer ... invasive bladder cancer [ID6301] Technology appraisal guidance Pegargiminase with ...

GUCS 2024 ctDNA Clearance Predicts Relapse Risk in Urothelial Cancer ... advanced non-small cell lung cancer (NSCLC)... Reuters Health Information, January 22, 2024 Alert FDA OKs Enfortumab ...